Stephen Nguyen, MD
Internal Medicine · Sun City, CANPI 1619976644
Payments from drug & device makers
Across 232 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$398
- Esperion Therapeutics, Inc.$374
- Novo Nordisk$371
- Boehringer Ingelheim$339
- Johnson & Johnson$334
- Sanofi-aventis U.S. LLC$296
- plus $3K from 36 others
What the payments were for
- Food & beverage$5,08998%
- Education$1102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 11 | $398 |
| Esperion Therapeutics, Inc. | 16 | $374 |
| Novo Nordisk | 22 | $371 |
| Boehringer Ingelheim | 15 | $339 |
| Johnson & Johnson | 19 | $334 |
| Sanofi-aventis U.S. LLC | 16 | $296 |
| Amgen | 6 | $273 |
| AstraZeneca | 15 | $266 |
| Lilly USA, LLC | 11 | $256 |
| AbbVie(2 entities) | 13 | $253 |
| Novartis | 14 | $246 |
| Astellas Pharma US Inc | 8 | $210 |
| Daiichi Sankyo Inc. | 1 | $180 |
| Otsuka America Pharmaceutical, Inc. | 6 | $147 |
| Corcept Therapeutics | 1 | $113 |
| Merck | 5 | $92 |
| GSK | 4 | $88 |
| Biodelivery Sciences International, Inc. | 5 | $83 |
| Eisai Inc. | 3 | $82 |
| Kowa Pharmaceuticals America, Inc. | 4 | $79 |
| Pfizer | 5 | $75 |
| Mannkind Corporation | 2 | $66 |
| Abbott | 2 | $49 |
| Abiomed | 1 | $44 |
| Almatica Pharma LLC | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $38 |
| Biogen | 2 | $36 |
| Intra-sana Laboratories | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $31 |
| Electromed, Inc. | 2 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Bayer | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $22 |
| Exact Sciences | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
| Qiagen, LLC | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,200 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $181,061 |
| OzempicSemaglutide | 121 | $149,748 |
| FarxigaDapagliflozin Propanediol | 79 | $85,429 |
| JardianceEmpagliflozin | 72 | $83,523 |
| HumiraAdalimumab | 13 | $78,170 |
| MounjaroTirzepatide | 39 | $55,463 |
| XareltoRivaroxaban | 44 | $48,172 |
| JanuviaSitagliptin Phosphate | 28 | $34,536 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $28,004 |
| TrulicityDulaglutide | 25 | $27,469 |
| VascepaIcosapent Ethyl | 29 | $23,892 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $18,198 |
| InvokanaCanagliflozin | 18 | $17,436 |
| EntrestoSacubitril/Valsartan | 12 | $15,198 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $14,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $75 | $181,061140 claims |
| Novo NordiskOzempic | $371 | $149,748121 claims |
| AbbVieHumira, Linzess, Synthroid | $253 | $92,841116 claims |
| AstraZenecaFarxiga | $266 | $85,42979 claims |
| Boehringer IngelheimJardiance | $339 | $83,52372 claims |
| Lilly USA, LLCMounjaro, Trulicity | $256 | $82,93264 claims |
| Johnson & JohnsonXarelto, Invokana | $334 | $65,60862 claims |
| MerckJanuvia, Janumet | $92 | $52,73441 claims |
| GSKTrelegy Ellipta | $88 | $28,00434 claims |
| NovartisEntresto | $246 | $15,19812 claims |
| Astellas Pharma US IncMyrbetriq | $210 | $13,74613 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $79 | $7,38418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Sun City
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.